• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Bristol-Myers Squibb Issues Statement in Response to Starboard’s Letter

Share:

March 3, 2019

Bristol-Myers Squibb Company today issued the following statement in response to a letter from Starboard Value:

Bristol-Myers Squibb welcomes the opinions of all of its stockholders and will review Starboard’s letter and respond in due course.

The Bristol-Myers Squibb Board and management team are confident that our combination with Celgene Corporation will create a premier biopharma company and deliver substantial benefits to our stockholders. This combination is consistent with our strategy and is the natural next step in the evolution of Bristol-Myers Squibb. As a combined entity, we will enhance our leadership positions across our portfolio, including in oncology, immunology and inflammation and cardiovascular. We will also benefit from an expanded early- and late-stage pipeline highlighted by six expected near-term product launches, including five from Celgene, representing more than $15 billion in total revenue potential. Together, our pipeline holds significant promise for patients, allowing us to accelerate new options through a broader range of cutting-edge technologies and discovery platforms.

The benefits of the combination are significant:

  • The Celgene transaction is the natural next step in Bristol-Myers Squibb’s proven strategy that has consistently delivered results for over a decade. Through a disciplined approach to driving innovation, focusing on high-value opportunities and sourcing innovation externally to complement its internal portfolio and pipeline, Bristol-Myers Squibb has generated consistently strong growth and increased its dividend for 10 consecutive years. The combination with Celgene will create a leading biopharma with increased scale, while maintaining the same agility and a focus on delivering for patients in core disease areas of high-unmet medical need.
  • The pipeline of the combined company provides significant near-, medium- and long-term opportunities for value creation. Bristol-Myers Squibb is acquiring Celgene’s robust and complementary pipeline at an attractive price. In addition to six expected near-term product launches, including five from Celgene’s strong pipeline, representing more than $15 billion in total revenue potential, the combination will greatly increase Bristol-Myers Squibb’s Phase I and II assets, which will provide the next set of registrational opportunities in core therapeutic areas. With an expanded set of scientific platforms and research capabilities, Bristol-Myers Squibb will be well positioned to discover and develop highly innovative medicines and accelerate these new options to patients through one of the highest-performing commercial organizations in the industry.
  • Bristol-Myers Squibb is well positioned for 2025 and beyond with continued leadership across Oncology and a diversified portfolio of assets. The combined company will have a broad, balanced and earlier life-cycle marketed portfolio with a significantly higher number of opportunities across multiple diseases to drive the growth of Bristol-Myers Squibb in the second half of the decade. These opportunities will support financial strength for continued investment and innovation.
  • The Celgene transaction is expected to generate meaningful financial benefits for all stockholders. With more than $45 billion of expected free cash flow generation over the first three full years post-closing, the combination will enable rapid debt reduction to de-lever the balance sheet and strengthen Bristol-Myers Squibb’s credit profile. Bristol-Myers Squibb expects to realize run-rate cost synergies of approximately $2.5 billion by 2022 from the combination, and the combined company is expected to grow revenue and EPS every year through 2025.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

The Bristol-Myers Squibb Board is composed of 11 highly qualified directors, 10 of whom are independent. The Company’s directors bring extensive leadership experience across a range of areas that are important to Bristol-Myers Squibb’s continued success, including health care, medical technology, and operations and finance. Moreover, the Company has demonstrated a consistent commitment to Board refreshment, having added six directors over the last three years.1

Bristol-Myers Squibb and Celgene continue to expect that the transaction will close in the third quarter of 2019, subject to approval by Bristol-Myers Squibb and Celgene stockholders and the satisfaction of customary closing conditions and regulatory approvals.

If Bristol-Myers Squibb stockholders have any questions or require assistance in voting their shares of Bristol-Myers Squibb stock, they should call MacKenzie Partners, Inc., Bristol-Myers Squibb’s proxy solicitor for its special meeting, toll-free at (800) 322-2885 or at (212) 929-5500.

Date: March 4, 2019

Source: Bristol Myers Squibb

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Altamont Capital Partners Acquires Publicis Healthcare SolutionsAltamont Capital Partners Acquires Publicis Healthcare Solutions
  • AbbVie buying Allergan for $63 billionAbbVie buying Allergan for $63 billion
  • Wearable Sensor Administers Narcan to Prevent Opioid Overdose DeathsWearable Sensor Administers Narcan to Prevent Opioid Overdose Deaths
  • iCoreConnect Acquires Assets of ClariCare Inc.iCoreConnect Acquires Assets of ClariCare Inc.
  • IntelyCare Launches Free COVID-19 Training for NursesIntelyCare Launches Free COVID-19 Training for Nurses
  • Pharmacy Inventory Management Software Solutions and Cabinets Market (impact of COVID-19) Growth, Overview with Detailed Analysis 2020-2026Pharmacy Inventory Management Software Solutions and Cabinets Market (impact of COVID-19) Growth, Overview with Detailed Analysis 2020-2026
  • Generational Equity Advises DoseLogix in Sale to Team TechnologiesGenerational Equity Advises DoseLogix in Sale to Team Technologies
  • Towa Pharmaceutical Co., Ltd. Reaches An Agreement with Esteve to Acquire Esteve’s Generic Division, Pensa InvestmentsTowa Pharmaceutical Co., Ltd. Reaches An Agreement with Esteve to Acquire Esteve’s Generic Division, Pensa Investments

Trending This Week

  • Chimerix Acquires Oncoceutics to Expand Pipeline with Late-Stage Oncology Program
  • Celularity and GX Acquisition Corp. Announce Merger Agreement to Create a Publicly Listed Leader in Allogeneic Cellular Therapy
  • Monroe Capital Supports Vivo Capital LLC’s Acquisition of Serán Bioscience, Inc.
  • Stryker Acquires OrthoSensor
  • PerkinElmer to Acquire Oxford Immunotec Global PLC
  • COVID-19’s Effect on Biopharma M&As in 2020

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications